Payers’ reaction to the IRA’s Medicare Part D Redesign
On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into…
CertaraAugust 25, 2023
Development and Verification of a Japanese Pediatric Physiologically Based Pharmacokinetic Model with Emphasis on Drugs Eliminated by Cytochrome P450 or Renal Excretion
Physiologically based pharmacokinetic (PBPK) models are useful in bridging drug exposure in different ethnic groups,…
CertaraAugust 21, 2023
Development and application of a PBPK modeling strategy to support antimalarial drug development
As part of a collaboration between Medicines for Malaria Venture (MMV), Certara UK and Monash…
CertaraAugust 18, 2023
Stop if you don’t have an unambiguous drug effect for your new molecular entity!
As a pharmacologist, I’ve always been curious about how drugs work. A favorite time-killer while…
CertaraAugust 18, 2023
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases
Successful clinical development of new therapeutic interventions is notoriously difficult, especially in neurodegenerative diseases, where…
CertaraAugust 15, 2023
IRA impacts: First 10 drugs selected for the Drug Price Negotiation Program
The Inflation Reduction Act (enacted in August 2022) contains profound changes for the healthcare and…
CertaraAugust 15, 2023
Secondary Intelligence™: Empowering Decision-Making in Drug Development & Safety Assessment
Adverse effects of drugs pose potential harm to patients and can hinder or halt the…
CertaraAugust 11, 2023
Model-Informed Formulation Development: Insights from a Case Study
In a captivating webinar led by industry experts, Dr. Swati Jaiswal, Senior PBPK Consultant at…
CertaraAugust 10, 2023
